Holzer & Holzer, LLC is investigating whether BELLUS Health, Inc. (“BELLUS Health” or the “Company”) (NASDAQ: BLU) complied with federal securities laws. On July 6, 2020, BELLUS Health announced the topline results from its Phase 2 RELIEF trial of BLU-5937, which showed the drug “did not achieve statistical significance for the primary endpoint of reduction in placebo-adjusted cough frequency at any dose tested.” The price of BELLUS Health stock fell following the announcement.

If you purchased shares of BELLUS Health and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Marshall P. Dees at mdees@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005827/en/